Natural products as a source of cytotoxic warheads in antibody-drug conjugates

References

• Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, Luo A, Ho PY, LeBlanc H, Blum LK, et al. 2021. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2(1):18–33.
   PubMedGoogle Scholar
• Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, ASCENT Clinical Trial Investigators, et al. 2021. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 384(16):1529–1541.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaïa N. 2017. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 16(5):315–337.
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. 2014. Antibody-drug conjugates: present and future. MAbs. 6(1):15–17.
   PubMed Web of Science ®Google Scholar
• Boger DL, Johnson DS. 1995. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc Natl Acad Sci U S A. 92(9):3642–3649.
   PubMed Web of Science ®Google Scholar
• Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, et al. 2018. MORAb-202, an antibody–drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity. Mol Cancer Ther. 17(12):2665–2675.
   PubMed Web of Science ®Google Scholar
• Chia CSB. 2022. A patent review on FDA-approved antibody-drug conjugates, their linkers and drug payloads. Chem Med Chem. 17(11):e202200032.
   Google Scholar
• De Cecco M, Galbraith DN, McDermott LL. 2021. What makes a good antibody–drug conjugate? Expert Opin Biol Ther. 21(7):841–847.
   PubMed Web of Science ®Google Scholar
• Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E, et al. 2014. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther. 13(11):2618–2629.
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. 2021. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol. 18(6):327–344.
   PubMed Web of Science ®Google Scholar
• Elias DJ, Hirschowitz L, Kline LE, Kroener JF, Dillman RO, Walker LE, Robb JA, Timms RM. 1990. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res. 50(13):4154–4159.
   PubMed Web of Science ®Google Scholar
• Fenton C, Perry CM. 2005. Gemtuzumab ozogamicin. Drugs. 65(16):2405–2427.
   PubMed Web of Science ®Google Scholar
• Fu Z, Li S, Han S, Shi C, Zhang Y. 2022. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 7(1):93.
   PubMed Web of Science ®Google Scholar
• Furuuchi K, Rybinski K, Fulmer J, Moriyama T, Drozdowski B, Soto A, Fernando S, Wilson K, Milinichik A, Dula ML, et al. 2021. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci. 112(6):2467–2480.
   PubMed Web of Science ®Google Scholar
• Goel B, Tiwari AK, Pandey RK, Singh AP, Kumar S, Sinha A, Jain SK, Khattri A. 2022. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma: an update on clinical trials. Transl Oncol. 21:101426.
   PubMed Web of Science ®Google Scholar
• Goldenson BH, Goodman AM, Ball ED. 2021. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Ther. 21(7):849–862.
   PubMed Web of Science ®Google Scholar
• Gregson SJ, Masterson LA, Wei B, Pillow TH, Spencer SD, Kang G-D, Yu S-F, Raab H, Lau J, Li G, et al. 2017. Pyrrolobenzodiazepine dimer antibody–drug conjugates: synthesis and evaluation of noncleavable drug-linkers. J Med Chem. 60(23):9490–9507.
   PubMed Web of Science ®Google Scholar
• He L, Wang L, Wang Z, Li T, Chen H, Zhang Y, Hu Z, Dimitrov DS, Du J, Liao X. 2021. Immune modulating antibody–drug conjugate (IM-ADC) for cancer immunotherapy. J Med Chem. 64(21):15716–15726.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Uemura D. 1986. Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl Chem. 58(5):701–710.
   Web of Science ®Google Scholar
• Kanellos J, Pietersz GA, McKenzie IFC. 1985. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. J Natl Cancer Inst. 75(2):319–332.
   PubMedGoogle Scholar
• Keam SJ. 2020. Trastuzumab deruxtecan: first approval. Drugs. 80(5):501–508.
   PubMed Web of Science ®Google Scholar
• Lamb YN. 2017. Inotuzumab ozogamicin: first global approval. Drugs. 77(14):1603–1610.
   PubMed Web of Science ®Google Scholar
• Lambert JM. 2005. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 5(5):543–549.
   PubMed Web of Science ®Google Scholar
• Lambert JM, Chari RVJ. 2014. Ado-trastuzumab emtansine (T-DM1): an antibody–drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 57(16):6949–6964.
   PubMed Web of Science ®Google Scholar
• Lee A. 2021. Loncastuximab tesirine: first approval. Drugs. 81(10):1229–1233.
   PubMed Web of Science ®Google Scholar
• Liao MZ, Lu D, Kågedal M, Miles D, Samineni D, Liu SN, Li C. 2021. Model-informed therapeutic dose optimization strategies for antibody–drug conjugates in oncology: what can we learn from us food and drug administration–approved antibody–drug conjugates? Clin Pharmacol Ther. 110(5):1216–1230.
   PubMed Web of Science ®Google Scholar
• Maderna A, Leverett CA. 2015. Recent advances in the development of new Auristatins: structural modifications and application in antibody drug conjugates. Mol Pharm. 12(6):1798–1812.
   PubMedGoogle Scholar
• Mantaj J, Jackson PJM, Rahman KM, Thurston DE. 2017. From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody–drug conjugates (ADCs). Angew Chem Int Ed Engl. 56(2):462–488.
   PubMed Web of Science ®Google Scholar
• Murray BC, Peterson MT, Fecik RA. 2015. Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers. Nat Prod Rep. 32(5):654–662.
   PubMed Web of Science ®Google Scholar
• Newman DJ. 2021. Natural product based antibody drug conjugates: clinical status as of November 9, 2020. J Nat Prod. 84(3):917–931.
   PubMed Web of Science ®Google Scholar
• Osgood CL, Chuk MK, Theoret MR, Huang L, He K, Her L, Keegan P, Pazdur R. 2017. FDA Approval summary: eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. Clin Cancer Res. 23(21):6384–6389.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, et al. 2016. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 77(1):155–162.
   PubMed Web of Science ®Google Scholar
• Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum AI, Liang M, He P, Marshall S, Scheuber A, et al. 2021. First-in-human, Phase 1 dose-escalation study of biparatopic anti-HER2 antibody–drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther. 20(8):1442–1453.
   PubMed Web of Science ®Google Scholar
• Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ. 1987. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc. 109(22):6883–6885.
   Web of Science ®Google Scholar
• Pettit GR, Singh SB, Hogan F, Lloyd-Williams P, Herald DL, Burkett DD, Clewlow PJ. 1989. Antineoplastic agents. Part 189. The absolute configuration and synthesis of natural (-)-dolastatin 10. J Am Chem Soc. 111(14):5463–5465.
   Web of Science ®Google Scholar
• Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K, Shimomura A, Ikezawa H, Nomoto M, Furuuchi K, et al. 2021. First-in-human Phase 1 study of MORAb-202, an antibody–drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-α–positive advanced solid tumors. Clin Cancer Res. 27(14):3905–3915.
   PubMed Web of Science ®Google Scholar
• Starling JJ, Maciak RS, Law KL, Hinson NA, Briggs SL, Laguzza BC, Johnson DA. 1991. In vivo antitumor activity of a monoclonal antibody-vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes. Cancer Res. 51(11):2965–2972.
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. 2008. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 8(6):473–480.
   PubMed Web of Science ®Google Scholar
• Syed YY. 2020. Sacituzumab govitecan: First approval. Drugs. 80(10):1019–1025.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Chari RVJ. 2011. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 17(20):6389–6397.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Meric-Bernstam F, McKean M, Beerli RR, Waldmeier L, Gebleux R, Hellmann I, Chrom P, Grawunder U. 2021. NBE-002: a novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial. JCO. 39(15_suppl):TPS1108–TPS1108.
   Web of Science ®Google Scholar
• Yao H-P, Zhao H, Hudson R, Tong X-M, Wang M-H. 2021. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov Today. 26(8):1857–1874.
   PubMed Web of Science ®Google Scholar
• Younes A, Yasothan U, Kirkpatrick P. 2012. Brentuximab vedotin. Nat Rev Drug Discov. 11(1):19–20.
   PubMed Web of Science ®Google Scholar
• Zein N, Poncin M, Nilakantan R, Ellestad George A. 1989. Calicheamicin γ1I and DNA: Molecular Recognition Process Responsible for Site-Specificity. Science. 244(4905):697–699.
   PubMed Web of Science ®Google Scholar
• Zein N, Sinha Achyut M, McGahren William J, Ellestad George A. 1988. Calicheamicin γ1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 240(4856):1198–1201.
   PubMed Web of Science ®Google Scholar